Human Reproductive Technologies Market is witnessing robust growth with Ferring Pharmaceuticals collaborating with Rebiotix Inc. and MyBiotics Pharma Ltd. to develop live microbiota-based biotherapeutics to address bacterial vaginosis, a common vaginal infection among women
Human Reproductive Technologies is
the use of science to help in the process of reproduction. The term Human
Reproductive Technologies covers all medical interventions that are used to
help people have children. The market for Human Reproductive Technologies is
very large and there are many aspects that affect the marketability of a
product. The overall costs of such procedures may vary from country to country
and may also depend upon the techniques that are being used to perform the procedure.
There is a high rate of infertility in North America due to high obesity rates,
which is leading to the increased adoption of human reproductive technologies.
As per the Centers for Disease Control and Prevention (CDC), in 2021, around
40% of adults aged 20 to 39 years were obese. On the contrary, Asia Pacific is
gaining significant traction in the human reproductive technologies market
since there is a high population coupled with growing awareness regarding
reproductive technologies.
The adoption of advanced human
reproductive technologies has increased over the years across the globe. Since
the cases of infertility are rising, the demand for effective reproductive
technologies is likely to increase. As per the World Health Organization (WHO),
in 2020, around 48 million couples and 186 million individuals live were with
infertility across the globe. Such high prevalence necessitates proper
treatment options. Thus, such factors can stimulate growth of the human
reproductive technologies market.
That being said, there are certain
challenges that could limit the adoption of human reproductive technologies
with limited insurance coverage being the one. Besides, there is low adoption
of human reproductive technologies in emerging economies, which could
potentially inhibit growth of the human reproductive technologies market in the
near future.
Another major area that the
reproductive technologies industry is currently focusing on is the treatment of
infertility caused by various factors. These factors range from age to genetics
and can be a very complicated problem that is why most doctors recommend their
patients to go under the care of an expert in the field. Infertility treatments
like in vitro fertilization or intrauterine insemination are fast rising and
have helped couples to have children despite being infertile. Another key
factor that has led to the high adoption of reproductive technologies is rising
prevalence of maternal mortality. As per the WHO, in 2017, around 810 women
died from preventable causes related to childbirth and pregnancy. Such factors
and lead to high demand for effective treatment methods and augment growth of
the human reproductive technologies market.
Recently, in February 2021, Ferring
Pharmaceuticals collaborated with Rebiotix Inc. and MyBiotics Pharma Ltd. to
develop live microbiota-based biotherapeutics to address bacterial vaginosis, a
common vaginal infection among women.
Comments
Post a Comment